Log in

Relevant bibliographies by topics / Cancer du sein basal-Like / Dissertations / Theses

To see the other types of publications on this topic, follow the link: Cancer du sein basal-Like.

Dissertations / Theses on the topic 'Cancer du sein basal-Like'

Author: Grafiati

Published: 30 November 2024

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 43 dissertations / theses for your research on the topic 'Cancer du sein basal-Like.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.

1

Aho, Simon. "Rôle de la voie BMP dans l'émergence des cellules souches cancéreuses mammaires et l'initiation du cancer du sein basal-like." Electronic Thesis or Diss., Lyon 1, 2024. https://theses.hal.science/tel-04811400.

Full text

Abstract:

Introduction : Le cancer du sein est la première cause de décès par cancer chez la femme dans le monde. Il s’agit d’une maladie hétérogène dont il existe plusieurs sous-types moléculaires corrélés au pronostic. Parmi ces différentes entités, le sous-type basal-like présente le pronostic le plus défavorable. Il est caractérisé par une expression accrue de marqueurs de différentiation basale et une instabilité génétique importante, fréquemment due à des altérations de la recombinaison homologue. Il est également enrichi en cellules souches cancéreuses. Ces cellules semblent être impliquées dans

APA, Harvard, Vancouver, ISO, and other styles

2

Yakhni, Mohamad. "Inhibition de la synthèse des protéines, un traitement adapté aux cancers du sein triple négatifs des sous-types moléculaires autres que basal-like 1." Thesis, Université Clermont Auvergne‎ (2017-2020), 2018. http://www.theses.fr/2018CLFAS025.

Full text

Abstract:

Les cancers du sein triple négatifs (CSTN), sans mutations dans les gènes BRCA1 ou BRCA2 ou sans BRCAness sont, aujourd’hui, les tumeurs malignes du sein les plus difficiles à traiter. L’amélioration de leur traitement, pour toutes les phases de la maladie, est un important besoin médical non satisfait. Nous avons analysé l’effet de l’homoharringtonine, un inhibiteur naturel de la synthèse des protéines, approuvé pour le traitement de la leucémie myéloïde chronique, sur quatre lignées cellulaires représentant des CSTN, appartenant aux catégories génomiques agressives, mais sans mutation de BRC

APA, Harvard, Vancouver, ISO, and other styles

3

Dufour, Robin. "Différentes approches de l'optimisation du traitement du cancer du sein de phénotype "basal like" triple négatif par un anti-PARP : contournement des protéines "Multidrug Resistance" et traitement combiné radiothérapie / chimiothérapie. Spécialité." Thesis, Clermont-Ferrand 1, 2016. http://www.theses.fr/2016CLF1MM05/document.

Full text

Abstract:

Le cancer du sein de phénotype « Basal-like » triple négatif (BLTN) est particulièrement agressif et de mauvais pronostic. Il est insensible aux traitements hormonaux laissant pour seule stratégie de traitement la chimiothérapie conventionnelle. De ce fait, de nouvelles thérapeutiques ciblées sont en développement, tels que les inhibiteurs de la Poly-ADP-Ribose-Polymerase (PARP). Dans ce contexte, nos travaux de recherche ont été orientés sur l’optimisation du traitement des cancers du sein BLTN en modélisant l’action d’un anti-PARP modèle, l’Olaparib sur la lignée SUM1315 de phénotype BLTN. D

APA, Harvard, Vancouver, ISO, and other styles

4

Hassanein, Mohamed. "Facteurs prédictifs de mutation germinale BRCA1 dans le cancer du sein héréditaire." Thesis, Aix-Marseille 2, 2010. http://www.theses.fr/2010AIX20714.

Full text

Abstract:

En France, le cancer de sein héréditaire représente environ 2500 nouveaux cas par an, dont prés de la moitié est attribuée à la mutation du gène BRCA1.La recherche de la mutation par biologie moléculaire est un travail fastidieux, coûteux et long (8 mois d’attente environ actuellement).Pour trouver une solution à ce délai, nous avons étudié en immunohistochimie une série initiale de 21 anticorps répartis en 5 groupes : anticorps antiBrca1 du commerce, liés à la perte de l’inactivation de l’X, liés à la signature basale ou myoépithéliale, anticorps dits classiques du cancer de sein et finalemen

APA, Harvard, Vancouver, ISO, and other styles

5

LEVY, RAFAEL. "Oncogenes, facteurs de croissance et cancers du sein : revue de la litterature, etude de la regulation du recepteur a l'igf 1 dans la lignee mcf-7 et des polymorphismes des proto-oncogenes c-ha-ras 1 et c-mos dans des cas familiaux." Lille 2, 1989. http://www.theses.fr/1989LIL2M316.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Jehanno, Charly. "Régulation de l'activité de récepteur alpha des oestrogènes (ERα) par l'hypoxie et le facteur MKL1 dans un modèle de cellules cancéreuses mammaires". Thesis, Rennes 1, 2017. http://www.theses.fr/2017REN1B050/document.

Full text

Abstract:

Les œstrogènes, et en particulier l’œstradiol E2, régulent un nombre considérable de fonctions physiologiques au sein de l’organisme et permettent notamment l’établissement et le maintien des fonctions reproductives chez tous les vertébrés. L’E2 agit localement dans de multiples organes cibles via l’intermédiaire de ses récepteurs : ERα et ERβ. Par son action proliférative contribuant au renouvellement de l’épithélium mammaire, l’E2 ainsi que son récepteur ERα ont été associés au développement pathologique de tumeurs mammaires. Celles-ci sont qualifiées d’hormono-dépendantes car elles réponden

APA, Harvard, Vancouver, ISO, and other styles

7

Confort, Carole. "Etude d'une forme soluble du récepteur IGFII/M6P dans les cancers du sein." Montpellier 1, 1995. http://www.theses.fr/1995MON1T025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Coutant, Pierre. "Valeur pronostique du dosage plasmatique de l'igf 1 dans le cancer du sein metastatique : etude portant sur 81 dossiers de patientes suivies au centre oscar lambret de lille." Lille 2, 1992. http://www.theses.fr/1992LIL2M238.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Bouchard, Alexanne. "La protéine de stress du réticulum endoplasmique GRP94 dans le cancer du sein triple négatif, intérêt diagnostique et thérapeutique." Electronic Thesis or Diss., Bourgogne Franche-Comté, 2023. https://nuxeo.u-bourgogne.fr/nuxeo/site/esupversions/8b1b931d-83a7-49fd-9779-012ad3949e79.

Full text

Abstract:

Le cancer du sein triple négatif (CSTN) est caractérisé par l’absence sur les cellules tumorales de récepteurs aux œstrogènes, à la progestérone ainsi que de HER2. Il s’agit du sous-type de cancer du sein le plus agressif et il est associé à un risque plus élevé de métastases. Il représente 15 à 20% de tous les cancers du sein. En raison du manque de cibles spécifiques, l'hormonothérapie et les médicaments ciblant HER2 sont inefficaces. Les CSTN représentent en fait un sous-groupe de tumeurs hétérogènes pouvant être classées en fonction de leurs caractéristiques moléculaires. Une meilleure com

APA, Harvard, Vancouver, ISO, and other styles

10

Houhou, Mona. "Caractérisation de sous-populations enrichies en cellules souches cancéreuses et rôle des régulateurs de la transition épithélio-mésenchymateuse dans la plasticité tumorale dans le cancer du sein de type basal." Thesis, Montpellier, 2017. http://www.theses.fr/2017MONTT043.

Full text

Abstract:

Il est généralement admis que le cancer du sein représente un ensemble de plusieurs maladies, définies comme des sous-types ayant des caractéristiques moléculaires et cliniques qui leurs sont propres. Une meilleure compréhension des mécanismes qui sous-tendent l'hétérogénéité du cancer du sein est essentielle au développement de thérapies mieux ajustées. Le concept de cellules souches cancéreuses (CSC) pourrait être un des clés de cette compréhension. A ce jour, un certain nombre de marqueurs ont été proposés pour isoler et caractériser les cellules souches dans le cancer du sein, mais aucun n

APA, Harvard, Vancouver, ISO, and other styles

11

Lemamy, Guy-Joseph. "Le récepteur humain du mannose-6-phosphate/IGFII : développement d'anticorps et premières études dans les cancers du sein." Montpellier 1, 1998. http://www.theses.fr/1998MON1T026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Villeneuve, Clémentine. "L'oncogène aPKCi, nouvel acteur de la dissémination tumorale précoce." Electronic Thesis or Diss., Paris Sciences et Lettres (ComUE), 2019. https://theses.hal.science/tel-02631809.

Full text

Abstract:

La formation de métastases issues de carcinomes est la principale cause de mortalité des cancers. Certaines cellules cancéreuses ont la capacité de s’échapper de la glande mammaire et former des métastases à un stade très précoce, bien avant la détection d’une tumeur primaire. Les mécanismes impliqués restent à être identifiés. L’extrusion basale pourrait être un des mécanismes impliqués dans la dissémination précoce de cellules cancéreuses. La perte de la polarité cellulaire est une des signatures des cellules cancéreuses. La protéine kinase C atypique iota (aPKCi) est un oncogène surexprimé

APA, Harvard, Vancouver, ISO, and other styles

13

張嘉慧 and Ka-wai Eva Cheung. "Granulin expression in basal-like breast cancer." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2008. http://hub.hku.hk/bib/B40738395.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Cheung, Ka-wai Eva. "Granulin expression in basal-like breast cancer." Click to view the E-thesis via HKUTO, 2008. http://sunzi.lib.hku.hk/hkuto/record/B40738395.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Moore, Madeleine. "Activating senescence in p16-positive Basal-like breast cancer." Thesis, Queen Mary, University of London, 2016. http://qmro.qmul.ac.uk/xmlui/handle/123456789/12985.

Full text

Abstract:

Breast cancer is the most common cancer in the UK and Basal-like breast cancer (a highly aggressive subtype) accounts for approximately 8-22% of all cases depending on ethnicity. Unlike most human malignancies and indeed other PAM50 breast cancer subtypes, the vast majority of Basal-like tumours are positive for wild type p16. This p16 signature is associated with a particularly poor prognosis and p16-positive Basal-like breast cancer remains the most clinically challenging subtype and is the focus of this project. Pro-senescence therapies are gaining momentum as attractive strategies for the

APA, Harvard, Vancouver, ISO, and other styles

16

Jo, Sung. "Targeting MSH2-MSH6 heterodimer in treating basal-like breast cancer." Thesis, University of Iowa, 2018. https://ir.uiowa.edu/etd/6153.

Full text

Abstract:

To identify novel therapeutic targets for basal-like breast cancer (BLBC) subtype, we investigated several DNA repair mechanisms associated with maintenance of high genomic instability for cell survival in cancer cells. We identified that the mismatch repair proteins, MSH2 and MSH6 (referred to as MSH2/6 hereafter), are highly elevated across BLBC samples. High expression level of MSH2/6 in BLBC is associated with worse prognosis and survivability for patients. Therefore, we knocked out MSH2 in BLBC

APA, Harvard, Vancouver, ISO, and other styles

17

KALOGRIS, Cristina. "Sanguinarine anti-tumor activity on a model of basal-like breast cancer." Doctoral thesis, Università degli Studi di Camerino, 2013. http://hdl.handle.net/11581/401698.

Full text

Abstract:

The aim of this work is to study the potential anti-proliferative effects of sanguinarine on mesenchymal cancer basal-like A17 cells isolated from FVB/neuT mammary carcinomas. Studies that have reviewed the histological presentation of basal-like breast cancer demonstrate that major90% of these tumors arise from the breast ducts and are often associated with higher nuclear and histological grade, high mitotic index and more aggressive phenotypic features. This clinical subset represents one of the most important treatment challenges today because these tumors are not likely to respond to hormo

APA, Harvard, Vancouver, ISO, and other styles

18

Matsumoto, Yoshiaki. "SALL4 - KHDRBS3 network enhances stemness by modulating CD44 splicing in basal-like breast cancer." Kyoto University, 2018. http://hdl.handle.net/2433/232117.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Alsabi, Qamar. "Characterizing Basal-Like Triple Negative Breast Cancer using Gene Expression Analysis: A Data Mining Approach." Wright State University / OhioLINK, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=wright1578936915199438.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Oliveira, Mónica Catarina Castro. "Proteasome-proteins: are these putative targets for basal-like breast cancer therapy with AAV-vectors?" Master's thesis, Universidade de Aveiro, 2016. http://hdl.handle.net/10773/18553.

Full text

Abstract:

Mestrado em Biologia Molecular e Celular<br>O cancro da mama do tipo basal (BLBC) é um grupo de tumores muito agressivo associado a um mau prognóstico. De momento, não existe nenhum tratamento eficaz para o BLBC, uma vez que rapidamente adquirem resistência às terapias normalmente usadas. Assim, é urgente encontrar novas abordagens para tratar esta doença. Com base em dados anteriores, o objetivo geral deste estudo foi avaliar se o PSMA2, uma proteína do proteassoma, seria um alvo putativo para a inibição para terapia em BLBC. Desta forma, o primeiro objetivo específico foi avaliar o efeito

APA, Harvard, Vancouver, ISO, and other styles

21

Wastall, Laura Mary. "The role of microRNAs in the fibroblasts of triple negative and basal-like breast cancer." Thesis, University of Leeds, 2017. http://etheses.whiterose.ac.uk/17798/.

Full text

Abstract:

Breast cancer is the second most common cancer worldwide and the fifth biggest cause of cancer-related deaths. Breast cancer subtype has a huge influence on tumour behaviour and prognosis. The basal-like subtype, which is typically – but not always – triple negative for receptor expression status limiting treatment options, represents one of the main subtypes with relatively poor prognosis. Breast cancer is a disease that comprises not only transformed luminal epithelial cells but also modified stroma, as a consequence of interactions between the cancer cells and the stroma. One of the most nu

APA, Harvard, Vancouver, ISO, and other styles

22

Stuart, Emma, and n/a. "Therapeutic potential of SERM and EGCG drug combinations for the treatment of basal-like breast cancer." University of Otago. Department of Pharmacology & Toxicology, 2009. http://adt.otago.ac.nz./public/adt-NZDU20090708.090405.

Full text

Abstract:

Basal-like breast cancer represents a subgroup of mammary cancers associated with a particularly poor prognosis, as they are refractory to current targeted therapies employed for the treatment of breast cancer. In this work I aimed to explore the therapeutic potential of selective estrogen receptor modulators (SERMs), a targeted breast cancer treatment, in combination with epigallocatechin gallate (EGCG), for the treatment of basal-like breast cancer, using MDA-MB-231 cell as an in vitro model of the disease. A significant reduction in MDA-MB-231 cell number and a significant increase in cytot

APA, Harvard, Vancouver, ISO, and other styles

23

Oram, L. "The role of p53 gain-of-function mutations in the pathogenesis of basal-like breast cancer." Thesis, Queen's University Belfast, 2014. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.680241.

Full text

Abstract:

Basal-like breast cancers (BLBC) are an aggressive sub-type of breast cancer which associates with high rates of proliferation and metastasis. However, the molecular mechanisms underlying these tumours are still largely unknown as most BLBC are also triple-receptor negative, which is defined by the lack of expression of oestrogen (ER) and progesterone (PR) receptors, with normal HER2 status. Consequently, there are currently no targeted therapies available for these tumours, which display the worst prognosis of all breast cancer subtypes. TP53 mutations occur within 20% of all breast tumours,

APA, Harvard, Vancouver, ISO, and other styles

24

D’Anello, Laura <1980&gt. "Epigenetic control of the basal-like gene expression profile via Interleukin-6 in breast cancer cells." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2011. http://amsdottorato.unibo.it/3368/1/d%27anello_laura_tesi.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

D’Anello, Laura <1980&gt. "Epigenetic control of the basal-like gene expression profile via Interleukin-6 in breast cancer cells." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2011. http://amsdottorato.unibo.it/3368/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

BADILLO, PAZMAY GRETTA VERONICA. "Anti-tumor activity of an arene ruthenium complex on a model of basal-like breast cancer." Doctoral thesis, Università degli Studi di Camerino, 2015. http://hdl.handle.net/11581/401740.

Full text

Abstract:

Background An arene ruthenium(II) complex containing neutral ligands and monoanionic nitrogen donators, has been prepared. The solid-state of the complex is an organometallic structure of half-sandwich (Arene)Ruthenium. The antiproliferative properties of this new ruthenium complex of general formula [Ru(cym)(L2)Cl]Cl, here called UNICAM1, was assessed by in vitro screening assays and in vivo mouse treatment against inoculation of A17 breast carcinoma triple negative cell line model. From our in-vitro result, it was found that the Ru-complexes exhibit lower antiproliferative activity against d

APA, Harvard, Vancouver, ISO, and other styles

27

Ho-Yen, Colan Maxwell. "The significance of c-Met in different molecular sub-types of invasive breast cancer." Thesis, Queen Mary, University of London, 2014. http://qmro.qmul.ac.uk/xmlui/handle/123456789/8907.

Full text

Abstract:

Introduction: Basal-like (BL) breast cancer is an aggressive sub-type of breast cancer for which there is no targeted systemic therapy. C-Met is a receptor tyrosine kinase implicated in breast cancer. Clinical trials assessing the efficacy of anti-c-Met therapy are underway, yet few studies have analysed the clinical significance of c-Met expression and/or activation in breast cancer, in particular whether there is a correlation with molecular sub-type. The aims of this study are: 1) to establish the clinical significance of c-Met expression in invasive breast cancer, 2) evaluate the novel pro

APA, Harvard, Vancouver, ISO, and other styles

28

Li, Wenzhao. "A homeobox protein, NKX6.1, up-regulates interleukin-6 expression for cell growth in basal-like breast cancer cells." Kyoto University, 2016. http://hdl.handle.net/2433/216184.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Tanaka, Sunao. "In silico analysis-based identification of the target residue of integrin α6 for metastasis inhibition of basal-like breast cancer". Kyoto University, 2020. http://hdl.handle.net/2433/253190.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Paul, Ritama. "Regulation of tumor growth and progression by Focal Adhesion Kinase (FAK) in a murine model of basal-like Breast Cancer." University of Cincinnati / OhioLINK, 2020. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1593268494905894.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Tkocz, D. "The characterisation of the transcriptional regulation of FOXC1 by BRCA1 and its role in the oncogenesis of basal-like breast cancer." Thesis, Queen's University Belfast, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.546436.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Balanis, Nikolas G. "DIVERSE ROLES FOR EGF RECEPTOR SIGNALING IN THE BREAST CANCER TUMOR MICROENVIRONMENT." Case Western Reserve University School of Graduate Studies / OhioLINK, 2013. http://rave.ohiolink.edu/etdc/view?acc_num=case1371572946.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

García, de la Fuente Isabel. "Caractérisation du carcinome mammaire de phénotype basal." Thèse, 2006. http://hdl.handle.net/1866/15753.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Grosset, Andrée-Anne. "Caractérisation du potentiel métastatique des carcinomes mammaires de phénotype basal." Thèse, 2009. http://hdl.handle.net/1866/3455.

Full text

Abstract:

Au Canada, on estime qu'une femme sur neuf développera un cancer du sein et qu'une femme sur vingt-huit en mourra. Les carcinomes mammaires de phénotype basal qui comprennent environ 15 à 25% des cancers envahissants du sein sont des tumeurs malignes ayant un très mauvais pronostic. Dans ce type tumoral, les métastases sont fréquentes et les décès nombreux. La formation des métastases est un processus complexe qui comprend plusieurs étapes; chacune peut être étudiée par des marqueurs spécifiques. Notre hypothèse de recherche est que le carcinome mammaire de phénotype basal possède des caractér

APA, Harvard, Vancouver, ISO, and other styles

35

Charlebois, Roxanne. "Le CpG et le poly(I:C) agissent en synergie avec le trastuzumab contre le cancer du sein HER2+." Thèse, 2015. http://hdl.handle.net/1866/13643.

Full text

Abstract:

Chez la souris, la thérapie anti-HER2 est dépendante de la présence de cellules T CD8+IFN-γ+ et des réponses IFN de type I. Ces IFN sont induits par les TLRs suite à la reconnaissance de signaux de danger, appelés PAMPs et DAMPs. Les TLR-3 et TLR-9 sont tous deux de bons inducteurs d’IFN de type I et sont également capable d’agir en synergie afin d’augmenter les niveaux d’IFN-γ, de TNF-α et d’IL-12. Notre hypothèse fut que la stimulation de ces deux TLRs mènerait à l’amélioration de l’activité anti-tumorale du trastuzumab via le recrutement et l’activation des cellules immunitaires. Nos buts f

APA, Harvard, Vancouver, ISO, and other styles

36

Pires, Maira Moura. "Basal-like breast cancer: modeling its initiation and characterizing novel EGFR variants." Thesis, 2012. https://doi.org/10.7916/D81J9HW4.

Full text

Abstract:

Breast cancer (BC) is now a disease that will affect 1 out of every 8 women worldwide. Due to its highly heterogeneous nature, BC is usually further classified into different subtypes according to gene expression profiling analysis. Basal-like breast cancer (BBC) accounts for 15-20% of all cases of BC. BBC is very aggressive, highly metastatic, and often lethal, mostly due to our poor understanding of the key genetic events that lead to the onset and/or maintain this subtype of BC. As a result, we currently lack targeted therapies that are otherwise very effective in some of the better underst

APA, Harvard, Vancouver, ISO, and other styles

37

Lien, Chi-Shun, and 連啟舜. "The associations between 5-MeC and overall survival in basal-like urothelial cancer." Thesis, 2018. http://ndltd.ncl.edu.tw/handle/yv457d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

"Cytotoxic Activity of Sphingosine-1-Phosphate against Human Triple-negative/ Basal-like Breast Cancer." Thesis, 2016. http://hdl.handle.net/10388/ETD-2016-01-2406.

Full text

Abstract:

Breast cancer is one of the most common malignancy diagnosed in women and is the primary cause of cancer-related deaths in women worldwide. It is a heterogeneous group of diseases that have a different response, prognosis, and clinical outcomes. Estrogen, progesterone and HER2 negative breast cancer, known as triple negative breast cancer (TNBC), does not respond to hormonal therapy. Basal-like breast cancer (BLBC) has shorter overall survival rate among other subtypes. Tumors sharing both TNBC and BLBC are considered less responsive to currently available treatment. Chemoresistance to treatm

APA, Harvard, Vancouver, ISO, and other styles

39

Elbanna, May F. M. "Investigating the Mechanisms of Resistance to Dual PI3K/MTOR Inhibitor in PIK3CA Mutant Basal Like Bladder Cancer." Diss., 2019. http://hdl.handle.net/1805/18939.

Full text

Abstract:

Indiana University-Purdue University Indianapolis (IUPUI)<br>Muscle invasive bladder cancer (MIBC) carries a poor prognosis where the overall 5 year survival ranges from 48% to 66%. To date, targeted therapies, except for immune checkpoint inhibitors have not been shown to be effective in the management of this disease, where conventional chemotherapy (i.e. cisplatin) continues to be the standard of care. Therefore, the challenge lies in identifying key molecular events that can predict response to targeted therapies and thereby provide patients with maximal clinical benefit. Using two MIBC p

APA, Harvard, Vancouver, ISO, and other styles

40

Faria, Lídia Maria Pereira. "Exploring the role of the actin-MRTFA-SRF signalling pathway downstream of P-cadherin in basal-like breast cancer cells." Master's thesis, 2021. https://hdl.handle.net/10216/138449.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Fagan-Solis, Katrina D. "Regulation and Action of Skp2 and Rhoa in Cell and Tumor Models: Investigation into the Molecular Mechanisms Responsible for the Aggressive Phenotype of Triplenegative Breast Cancer." 2013. https://scholarworks.umass.edu/open_access_dissertations/683.

Full text

Abstract:

Breast cancer tops the list of new cancer cases and is predicted to be the second leading cause of cancer deaths in women in 2012. The primary objective of the present study was to provide insights into the molecular mechanisms underlying the aggressive growth and metastasis of triple-negative and basal-like breast cancers. To study increased growth and invasive behavior in triple-negative and basal-like breast cancers we utilize both an interesting and relevant cell culture model and examination of human tissue. In this study, we use the Tamoxifen-selected, MCF-7 derivative, TMX2-28 breast ca

APA, Harvard, Vancouver, ISO, and other styles

42

Goldvasser, Pavel. "Identification of Novel Notch Target Genes in Breast Cancer." Thesis, 2011. http://hdl.handle.net/1807/30607.

Full text

Abstract:

Notch signaling plays a key role in development, tissue homeostasis, and cancer. High expression levels of Notch signaling components are associated with aggressive disease and poor patient prognosis in breast cancer. Mesenchymal‐epithelial transition factor (MET) is a receptor tyrosine kinase with an established prognostic significance correlating with poor disease outcome in breast cancer patients as a result of high metastatic rate. We performed expression array analysis to identify candidate Notch target genes; we identified and validated MET as a target of NOTCH1 signaling in breast cance

APA, Harvard, Vancouver, ISO, and other styles

43

Kuo, Wen Ling, and 郭玟伶. "Establishment of Basal-like Cell Lines from Asian Breast Cancer Patients and Exploring the Mechanism Involving Tumor Immune Modulation via 14-3-3zeta in Triple Negative Breast Cancer Mouse Model." Thesis, 2018. http://ndltd.ncl.edu.tw/handle/6qsar3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!